FDA has published 33 product-specific recommendations (18 new and 15 revised) describing the Agency’s current thinking and expectations on how to develop generic drug products that are therapeutically equivalent to specific reference-listed drugs.
FDA always seeks feedback and considers all comments to the docket before it begins work on the final versions of BE guidances.
For more information and to view the recommendations, visit http://www.fda.gov/drugs/
guidancecomplianceregulatoryin formation/guidances/ucm075207. htm